What HPAPI Containment Means in CDMO Selection

When a small molecule development programme involves a high-potency Active Pharmaceutical Ingredient (HPAPI), selecting the right Contract Development and Manufacturing Organisation (CDMO) becomes a decision with direct consequences for operator safety, product quality and regulatory compliance. Containment capability is not a secondary specification: it is a primary qualification criterion. This guide explains the technical and regulatory requirements that pharmaceutical and biotechnology development leaders should evaluate when selecting an integrated CDMO for HPAPI small molecule formulation development. It covers Occupational Exposure Band classification, containment engineering controls, cleaning validation methodology and the Good Manufacturing Practice (GMP) expectations that define credible, verified capability.

1. What Is a High-Potency Active Pharmaceutical Ingredient?

A high-potency Active Pharmaceutical Ingredient is a compound that produces a pharmacological or toxicological effect at very low doses. In occupational hygiene terms, this is defined by an Occupational Exposure Limit (OEL) at or below 10 micrograms per cubic metre of air (µg/m³), though some definitions apply thresholds of 1 µg/m³ or below for the most potent categories. HPAPIs span a wide range of therapeutic classes, including oncology compounds, targeted kinase inhibitors, hormones, immunosuppressants and select cardiovascular agents. The biological potency that makes these molecules therapeutically valuable also creates two distinct and parallel obligations for any manufacturing organisation:

• Protecting operators through robust, validated containment engineering
• Protecting patients through demonstrable cross-contamination prevention

A CDMO that cannot evidence both obligations through documentation, validated data and regulatory inspection history should not be considered a viable partner for HPAPI small molecule development.

2. Understanding Occupational Exposure Bands

The Occupational Exposure Band (OEB) system is the primary industry framework for classifying compounds according to their toxicological potency and the level of engineering control required during handling. OEB classification is assigned by a qualified occupational hygienist or toxicologist, using available data from acute and chronic toxicity studies, carcinogenicity and reproductive toxicity assessments and pharmacological activity profiles.

Where data are incomplete, the principle of conservative assignment applies: the compound is
classified at the lower, more restrictive band until sufficient evidence is available to support reclassification.

OEB 1 to OEB 5: Classification and Containment Requirements

Some CDMOs extend the banding system to an OEB 6 category, covering highly potent biological conjugates such as antibody-drug conjugates, where Occupational Exposure Limits fall below 0.1 µg/m³. Buyers should confirm whether the prospective CDMO’s internal banding system aligns with the classification applied by their own occupational hygiene function.

How OEB Classification Drives Facility Requirements

OEB classification directly determines the physical infrastructure, operational procedures and analytical
capabilities required before a compound can be handled. A facility claiming OEB 4 capability must demonstrate isolator-grade containment with validated Containment Performance Testing data. A facility claiming OEB 5 capability must meet a significantly more stringent standard, with documented performance results typically expressed as nanogram-level surface wipe results or sub-microgram-per-cubic-metre airborne concentrations.

Buyers should request documentary evidence of containment performance, including Containment Performance Testing reports conducted under simulated operational conditions, before accepting any verbal representation of OEB capability.

3. Containment Engineering Controls: What to Verify

Engineering controls form the primary barrier between an HPAPI and the operator. The hierarchy of controls must be evaluated systematically across the full manufacturing process, from receipt and weighing through to waste disposal.

Isolators and Restricted Access Barrier Systems

For OEB 4 and OEB 5 compounds, isolator technology is the accepted standard. An isolator is a rigid physical enclosure within which all product-contact operations are performed through integrated gloves and half-suits. Isolators may be configured for:

• Negative pressure operation to protect the operator from the compound (standard for potent compound handling)
• Positive pressure operation to protect the product from environmental contamination
• Combined pressure cascade designs where both protections are required simultaneously

A Restricted Access Barrier System (RABS) provides a lower level of physical separation and is
generally appropriate for lower-band HPAPI handling or as a supplementary control. RABS should not be accepted as equivalent to isolator containment for OEB 4 or OEB 5 compounds unless supported by specific Containment Performance Testing data demonstrating equivalent performance.

When evaluating a CDMO, buyers should confirm:

• The OEB rating and validated performance of each containment system installed
• Whether transfer ports use Rapid Transfer Port or Split Butterfly Valve technology to eliminate open powder handling between enclosures
• The date and outcome of the most recent Containment Performance Test

Contained Transfer Technologies

Material movement between process steps is one of the highest-risk points for containment failure. Contained transfer systems, including split butterfly valves, contained bag-in/bag-out filter housing systems and
single-use flexible containment liners, eliminate open powder handling throughout the process.

Buyers should ask a prospective CDMO to describe, step by step, how material is transferred during each of the following: receipt and quarantine, dispensing and weighing, blending, granulation or milling, compression or encapsulation, filling and waste handling. Any open transfer step between enclosed zones represents a containment gap that must be justified and controlled.

Ventilation Design and Pressure Differentials

The heating, ventilation and air conditioning design of an HPAPI suite is as operationally significant as the equipment installed within it. Negative pressure rooms prevent airborne compound migration to adjacent areas.
Buyers should verify:

• Air change rates per hour in containment and buffer zones
• The pressure differential cascade from general facility areas through to the highest-containment zone
• The facility’s continuous environmental monitoring capability for airborne particulates and real-time pressure differential alarms

4. Cleaning Validation in HPAPI Facilities

Where a CDMO operates on shared equipment or in shared suites across multiple HPAPI compounds,
cleaning validation is a direct patient safety control. Its purpose is to demonstrate that residues of a previous compound are reduced to a concentration that cannot cause harm in a patient receiving the subsequent product.

Health-Based Exposure Limits and Maximum Allowable Carryover

The European Medicines Agency’s guideline on setting health-based exposure limits or use in risk identification during shared-facility manufacturing established the Acceptable Daily Exposure (ADE) and Permitted Daily Exposure (PDE) as the required basis for calculating Maximum Allowable Carryover (MACO) values.

The Maximum Allowable Carryover value defines the maximum quantity of a previous compound permissible on equipment surfaces before the next campaign begins. For HPAPIs, these values can fall into the nanogram to low-microgram range, placing considerable demands on analytical sensitivity and sampling methodology.

Buyers should confirm that a prospective CDMO:

• Calculates cleaning acceptance limits using compound-specific Acceptable Daily Exposure and Permitted Daily Exposure values derived by a qualified toxicologist
• Does not rely on legacy methods such as the 10 parts per million criterion or dose-fraction approaches as the primary basis for limit setting
• Holds documented cleaning validation data demonstrating that acceptance limits are consistently met across the relevant equipment train

Analytical Methods for Cleaning Verification

The two principal sampling approaches for HPAPI cleaning verification are swab sampling and rinse sampling. Swab samples are typically analysed by high-performance liquid chromatography with validated specificity for the compound in question, or by Total Organic Carbon analysis as a non-specific
surrogate method.

For HPAPI compounds at very low Maximum Allowable Carryover values, specificity matters. Buyers should confirm:

• The validated lower limit of quantification of the analytical method in use and whether this falls below the calculated Maximum Allowable Carryover value
• Whether a compound-specific validated method exists or whether Total Organic Carbon analysis is being used as a default surrogate, and whether the CDMO can justify that approach for the compound’s potency class
• The qualification status of sampling personnel and the validated swab recovery factors applied to results

5. GMP Compliance Expectations for HPAPI Manufacturing

Regulatory expectations for HPAPI handling are embedded across multiple frameworks. Development leaders should understand the relevant guidance before initiating due diligence with any prospective CDMO.

Regulatory Frameworks Governing HPAPI Handling

The primary regulatory reference points for HPAPI manufacturing in Europe include:

• EU Good Manufacturing Practice guidelines, particularly Annex 15 (Qualification and Validation) and the broader GMP Chapter 3 requirements for premises and equipment.

In the United States, Title 21 of the Code of Federal Regulations Part 211 governs current Good Manufacturing Practice for finished pharmaceuticals, and the Food and Drug Administration has issued guidance on preventing cross-contamination in pharmaceutical manufacturing.

Buyers should verify that a CDMO holds a current Manufacturing and Import Authorisation or
equivalent national authorisation explicitly covering the relevant dosage forms and potency classes. They should also request the date and summary outcome of the facility’s most recent GMP inspection by the relevant national competent authority.

6. Dedicated vs. Campaign Manufacturing: Risk Implications

A CDMO may handle HPAPI compounds on dedicated equipment, used exclusively for potent compound manufacturing, or on shared equipment cleaned between product campaigns. Each approach carries different implications for validation requirements, scheduling and risk management.

Buyers should establish which model applies to their compound at each development stage and confirm whether cleaning validation studies have been conducted between compound classes of differing potency within the same equipment train.

7. Key Technical Questions for CDMO Evaluation

When assessing a CDMO’s HPAPI formulation development capability, development leaders should structure their technical due diligence around the following areas.

Containment Infrastructure

• What is the maximum OEB level the facility is validated to handle, and what performance data supports this claim?
• Are contained transfer systems in place at every step involving open powder handling?
• How is ventilation performance for containment suites monitored and alarmed in real time?

Cleaning Validation

• Are cleaning acceptance limits set using compound-specific Acceptable Daily Exposure and Permitted Daily Exposure values from a qualified toxicologist?
• What analytical method is used for HPAPI residue detection, and what is the validated lower limit of quantification?
• Can the CDMO provide anonymised cleaning validation summary data from previous HPAPI programmes as a reference point?

Regulatory and Quality Status

• What GMP authorisations cover the HPAPI suite, and when were they last reviewed or inspected?
• What was the outcome of the most recent regulatory inspection, and were any findings related to containment or cleaning validation?
• Has the facility previously supported HPAPI compounds through clinical development phases?

Development Integration

• Does the CDMO offer integrated formulation development for HPAPI small molecules, from preformulation and formulation screening through to clinical manufacturing?
• Does the organisation have small-scale containment equipment appropriate for early-phase programmes with limited Active Pharmaceutical Ingredient quantities?
• Can the analytical team develop and validate HPAPI-specific methods in parallel with formulation development activities?

8. How Adragos Pharma Supports HPAPI Small Molecule Development

Adragos Pharma provides integrated HPAPI small molecule formulation development and manufacturing through its dedicated facility in Athens, Greece.

A Dedicated, EU-GMP Certified HPAPI Suite

The dedicated suite forhigh-potency Active Pharmaceutical Ingredient products at the Athens facility has been certified as EU-GMP compliant by the Greek Regulatory Authorities since 2023. This certification confirms that the site operates within a defined and inspected quality framework appropriate for the handling and manufacture of highly potent compounds.

The Athens HPAPI suite is equipped to handle compounds up to and including Occupational Exposure Band 5, covering the most demanding category of small molecule potency in standard industry classification. This positions Adragos as a capable partner for development programmes involving oncology agents, hormone-based therapies, targeted kinase inhibitors and other compound classes where stringent occupational exposure controls are required.

Laboratory-Scale Manufacturing for Solid and Liquid Dosage Forms

The HPAPI laboratory at the Athens site encompasses a dedicated lab-scale manufacturing area designed for the research and development production of both  solid and liquid pharmaceutical products containing high-potency Active Pharmaceutical Ingredients. This dual-format capability allows development teams to progress formulation strategies across a range of dosage form types within a single contained environment, without the need to transfer programmes to external sites during early-stage development.

Integrated Analytical Capability

Co-located within the Athens HPAPI suite is a dedicated analytical laboratory, supporting the analysis of both liquid and solid pharmaceutical products and active substances in accordance with GMP requirements. This integrated analytical infrastructure enables formulation development and analytical method development to proceed in parallel, reducing the timeline risks that commonly arise when these activities are physically or organisationally separated.

A Skilled and Specialised Team

The Athens HPAPI facility is supported by highly skilled professionals with specific expertise in high-potency compound handling. For pharmaceutical and biotechnology development leaders seeking a CDMO with demonstrable OEB 5 capability, EU-GMP certification and integrated analytical support, the Adragos Athens facility provides a structured, compliant environment for programmes from early research and development through to clinical manufacturing.

Explore Our HPAPI Capabilities →

Conclusion

HPAPI containment capability cannot be taken on the basis of assertion. A CDMO’s qualification to handle
high-potency compounds must be substantiated by a current GMP authorisation covering the relevant potency class, engineering infrastructure appropriate to the compound’s Occupational Exposure Band and a quality system that supports the full analytical and validation requirements of high-potency manufacturing.

For pharmaceutical and biotechnology development leaders selecting an integrated CDMO for HPAPI small molecule formulation development, a structured due diligence process, focused on the technical and compliance criteria outlined in this guide, is the most reliable means of identifying a partner with genuine, verified capability.